Urine collection device takes the prize

A new urine collection device for women has been acclaimed as Best Industrial Product and Best of Show at the Design Week Awards. The...

GSK completes acquisition of Stiefel

GSK has completed its acquisition of Stiefel, creating a new world-leading specialist dermatology business with revenues of approximately $1.5 billion. GSK has acquired the...

London to gain 12 new stroke and trauma centres

Patients in London who have suffered a major trauma or stroke will benefit from 12 new emergency care units planned by a joint committee...

Aberdeen hospital gains faster scanner

Aberdeen Royal Infirmary has strengthened its imaging facilities with the installation of a SPECT system from Siemens Healthcare. The Symbia S scanner will enable...

NICE should relax pricing rules, says Kennedy report

NICE should relax its rules on pricing for drugs that offer the most benefits to patients, an independent study has concluded. The proposal forms...

First UK drug approval for rare disease

Actelion’s Zavesca (miglustat), the only licensed treatment for Niemann-Pick type C (NP-C) disease, has been approved in the UK and the Republic of Ireland....

Eizo resources PACS in Northern Ireland

Monitor supplier Eizo has been contracted to provide medical monitors for PACS systems throughout the Northern Ireland NHS. Medical IT company Sectra, the prime...

Sandoz launches third biosimilar in the UK

Sandoz has launched its recombinant granulocyte colony-stimulating factor (G-CSF) Zarzio (filgrastim) in the UK. Zarzio is approved as a treatment for neutropenia (low white...

Park House Healthcare celebrates 25 years

Yorkshire-based company Park House Healthcare has celebrated its 25th anniversary as a supplier of pressure relief equipment and services. At an evening celebration, founder...

EC investigates pharma competition

 The European Commission has issued its final report following an EU investigation into competition within the pharma sector. The 18-month inquiry found that seven-month...

Latest articles

Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer

Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab)

Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab) in early or locally advanced HER2-positive breast cancer. Samsung Bioepis has announced the findings of...
Servier enters collaborative study with Harvard University researchers

Servier & Harvard researchers collaborate to develop therapeutics

Servier has entered into a collaborative study with Harvard University researchers to explore a new avenue for the treatment of type 2 diabetes and...
2019 HSJ Partnership Awards winners

2019 HSJ Partnership Awards winners

The 2019 HSJ Partnership Awards winners have been announced and they showcased effective partnership working within the NHS. With more than 700 NHS partners and...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...

Market Access in practice: do you have a strategy?

This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...
Kate Lancaster is the new RCOG Chief Executive

Kate Lancaster will be the new RCOG Chief Executive

Kate Lancaster, the Director of Strategy at East and North Hertfordshire NHS Trust will be the new RCOG Chief Executive.  The Royal College of Obstetricians...
Health experts alarmed at rise in joint health conditions.

UK launch of Jorveza announced for the treatment of EoE

Dr Falk Pharma UK announces the UK launch of Jorveza, the first globally licensed drug approved for the treatment of the immune mediated, chronic...